Renal Cell Carcinoma

New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC

2023-08-20

  • Study

    Single-arm, open-label, multicenter, phase II trial Previously untreated stage IV non-clear cell renal cell carcinoma
    Pembrolizumab + Lenvatinib (n=158


  • Efficacy

    cORR: 49% [78 of 158 pts]
    CR: 6% [ 9 of 158 pts]
    mPFS: 18.0 mos [14-NR]
    12 mos PFS: 63% [54-70]
    12 mos OS: 82% [72-88]

  • Safety

    Grade3: Hypertesion (23%), proteinuria (4%), stomatitis (4%)


    • LANCET Oncol, VOL 24, ISSUE 8, P881-891, AUG 2023

    Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

    http://doi.org/10.1016/S1470-2045(23)00276-0

    Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023